Pharmaceutical Contract Manufacturing Industry Trends

The emergence of novel biopharmaceutical therapeutic modalities, such as antibodies, cell therapies and gene therapies, has led to the modernization of the overall treatment procedure, which has made the pharmaceutical development and manufacturing processes even more complex. As a result, the pharmaceutical industry is unable to cater to the growing demand across various therapeutic areas. Henceforth, outsourcing has become a prominent trend to meet the increasingly complex demands of industry, especially for aseptic fill / finish manufacturing. Pharmaceutical contract manufacturing industry has swiftly adapted to this shifting terrain by leveraging advanced technologies to meet the evolving needs during drug development and production.

Presently, there are a number of contract development and manufacturing companies that cater to the needs of pharmaceutical companies worldwide. Commonly outsourced processes in the pharmaceutical contract manufacturing industry include formulation design, dosage form development, clinical / commercial production, packaging, and distribution. Further, modern contract manufacturers also offer non-core services, such as clinical research, clinical trial management, sales, and marketing, as well. Moreover, there are a number of end-to-end service providers that offer services across the pharmaceutical value chain. However, there are certain players in the industry that continue to focus on providing exclusive and customized offerings in niche areas.

Given the rising demand for pharmaceutical’ small molecules, along with the rise in mergers and acquisitions, and expansion activity, the pharmaceutical contract manufacturing market is likely to experience substantial growth in the coming years.

Roots Analysis has conducted an exhaustive study on Pharmaceutical Contract Manufacturing Market featuring the current market landscape and future opportunity for the companies engaged in offering services for pharmaceutical contract manufacturing, till 2035. In this article, we have highlighted some of the latest pharmaceutical contract manufacturing industry trends that are likely to shape the evolution of the market.

Want to explore the latest Pharmaceutical Contract Manufacturing Industry Trends?

Latest Trends in Pharmaceutical Contract Manufacturing Industry that are Likely to Shape the Market

1. Growing Pipeline of Small Molecules: Driving Pharmaceutical Manufacturing

The current small molecules pipeline features over 9,000 molecules that are currently under development for the treatment of various disease indications. Further, it is worth highlighting that, over 15,000 small molecules have been approved till date. The presence of these multiple late-stage candidates indicates several short and mid-term opportunities for the companies engaged in pharmaceutical contract manufacturing market. Further, as small molecule pipelines expands beyond stagnant periods, contract manufacturing organizations (CMOs) offering end-to-end services from API production to finished dosage forms emerge as critical allies, thereby guaranteeing supply reliability and stringent compliance for therapies targeting high-burden conditions.

2. Pharmaceutical Contract Manufacturers: Accelerating Market Access and Cost Efficiency

Pharmaceutical CMOs are rapidly accelerating market access and enhancing cost efficiency for innovators across the biopharma sector. By leveraging specialized expertise, scalable infrastructure, and advanced technologies like continuous manufacturing and AI-driven process optimization, these CMOs enable faster development timelines, while minimizing capital expenditures for sponsors. This partnership model reduces operational risks, streamlines supply chains, and ensures regulatory compliance, thereby allowing companies to focus more on their core competencies such as, research and development. Currently, close to 510 players are actively engaged in offering pharmaceutical contract manufacturing services; of these, ~15% players have been established post-2010. Notable examples of the players established in 2024 include (in alphabetical order) EthixElite, Hycon and Merrals Overseas.

3. AI and Digital Integration: Transforming the Pharmaceutical Contract Manufacturing Industry

AI and digital integration are transforming pharmaceutical contract manufacturing industry by enabling smarter, more predictive operations across the value chain. Many CMOs are leveraging artificial intelligence for real-time process optimization, predictive maintenance, and quality control. This helps in reducing the downtime and ensuring consistent yields in the production of complex biologics. Further, technologies such as, digital twins and advanced analytics facilitate scenario modeling for capacity planning and supply chain resilience, while machine learning algorithms accelerate batch release and regulatory compliance through automated data integrity checks. These innovations empower CMOs to provide accelerated timelines, enhanced reliability, and seamless scalability for bringing cutting-edge therapies to market.

4. Mergers and Acquisitions: Driving Consolidation and Growth

Recently, there has been a rise in the number of mergers and acquisitions in the pharmaceutical contract manufacturing industry. This can be attributed to the growing need for enhanced operational efficiency, gaining new capabilities and a quest to gain competitive advantage over the competitors engaged in this domain. Notably, majority of the players headquartered in Europe are expanding their capabilities by signing international agreements; examples of instances undertaken in Q3 2025 include (in alphabetical order) company acquisition of Regis Technologies by Esteve (July), and company acquisition of XGX Pharma by Unimedic Pharma (July).

5. Recent Expansions: Targeted Towards Expanding the Overall Production Capacity

From Q3 2024 - Q3 2025, more than 75 expansion initiatives have been undertaken by companies engaged in the pharmaceutical contract manufacturing domain; such initiatives assist in enhancing the existing capabilities of CMOs in the pharmaceutical contract manufacturing industry. Notably, most of the initiatives were focused on establishing new facilities; this will help in significantly boosting the production capacity of CMOs, enabling them to meet surging demand for complex therapies and scale operations efficiently. Examples of players that have established new facility in Q3 2025 include (in reverse chronological order) AbbVie Contract Manufacturing (August 2025), Polfa Tarchomin (August 2025), Suven Life Sciences (August 2025), ClearSynth (July 2025) and McGuff Pharmaceuticals (July 2025).

6. North America: Leading the Pharmaceutical Contract Manufacturing Market

Currently, North America captures majority (~45%) of the market share in the pharmaceutical contract manufacturing market. This can be attributed to well-established pharmaceutical contract manufacturing industry, along with robust infrastructure and significant investments in research and development of manufacturing technologies within this region. Additionally, North America has a substantial demand for both generic and specialty drugs, which further drives the growth.

Conclusion

The pharmaceutical contract manufacturing landscape is moving toward a more innovative and efficient future as technology advances and the demand for new therapies grows. In this changing environment, CMOs are adapting to major industry trends, such as personalized medicine, precision therapeutics, continuous manufacturing, supply chain optimization, and digital health integration. At the same time, rising expectations for sustainability is pushing them to adopt greener manufacturing methods, while strict regulatory compliance and strong quality assurance remain essential. Driven by these initiatives, CMOs are expected to play an increasingly important role in shaping the future of healthcare.

Browse our full report on Pharmaceutical Contract Manufacturing Market: https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market/191.html#overview

Sources:

1. https://www.lonza.com/annualreport/2024/our-businesses/small-molecules#
2. https://go.drugbank.com/stats